# TransMedics: 3 Key Takeaways for Long-Term Investors

> TransMedics raises 2026 revenue guidance to $774 million with strong quarterly growth.
- Title: TransMedics: 3 Key Takeaways for Long-Term Investors
- Summary: TransMedics raises 2026 revenue guidance to $774 million with strong quarterly growth.
- Keywords: transmedics, revenue guidance, organ preservation, clinical testing, kidney preservation, The Motley Fool
- Source: The Motley Fool — https://fool.com/earnings/takeaways/2026/11/09/transmedics-3-key-takeaways-for-long-term-investors
- Author: The Motley Fool Team
- Published: 2026-11-10T00:36:59+00:00
- Read time: 1 min
- Topics: transmedics, revenue guidance, organ preservation, clinical testing, kidney preservation, finance, money
## 2026 Revenue Guidance
TransMedics raised 2026 revenue guidance to $764 million to $774 million.
## Third-Quarter Revenue Growth
Third-quarter revenue reached $203 million, up 41% year over year.
## OCS Kidney Clinical Testing
OCS Kidney clinical testing remains on track for late 2027.
## ENHANCE Heart and DENOVO Lung Programs
ENHANCE Heart and DENOVO Lung programs target 2,000 to 5,000 additional annual procedures.
## Key takeaway

TransMedics raised 2026 revenue guidance to $774 million as third-quarter revenue reached $203 million, up 41% year over year.